Shareholder Vote

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) – May 24, 2022 WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter) Pennsylvania 1-8036 23-1210010 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 530 Herman O. West Drive , Exton , PA 19341-0645 (Address of principal executive offices) (Zip Code)  Registrant’s telephone number, including area code: 610 - 594-2900 Not Applicable (Former name or address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol Name of each exchange on which registered Common Stock, par value $0.25 per share WST New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ 1 Item 5.07 Submission of Matters to a Vote of Security Holders. Our 2022 Annual Meeting of Shareholders was held virtually on May 24, 2022. Our shareholders voted on three proposals at the Annual Meeting. The proposals are described in detail in our proxy statement dated April 14, 2022. As of March 1, 2022, the record date, there were 74,353,269 shares of our common stock outstanding. Shareholders representing 68,343,988 or 91.91%, of the common shares outstanding were present virtually or were represented by proxy at the Annual Meeting. The final results for the votes on each proposal are set forth below. Proposal 1: Our shareholders elected the following directors to serve on our Board until the 2023 Annual Meeting of Shareholders by the following vote: Name For Against Abstain Broker Non-Votes Mark A. Buthman 61,794,515 3,730,075 106,464 2,712,934 William F. Feehery 46,726,269 16,116,249 2,788,536 2,712,934 Robert F. Friel 64,974,805 549,698 106,551 2,712,934 Eric M. Green 60,846,813 1,991,272 2,792,969 2,712,934 Molly E. Joseph 65,299,365 216,521 115,168 2,712,934 Thomas W. Hofmann 62,469,105 3,055,515 106,434 2,712,934 Deborah L. V. Keller 62,132,767 3,391,689 106,598 2,712,934 Myla P. Lai-Goldman 65,157,051 367,116 106,887 2,712,934 Douglas A. Michels 62,990,407 2,533,431 107,216 2,712,934 Paolo Pucci 65,138,923 385,374 106,757 2,712,934 Proposal 2: Our shareholders approved, on an advisory basis, our named executive officer compensation by the following vote: For Against Abstain Broker Non-Votes 61,054,162 4,442,778 134,114 2,712,934 Proposal 3: Our shareholders ratified the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the 2022 fiscal year by the following vote: For Against Abstain 62,261,026 5,980,431 102,531 Item 9.01 Financial Statements and Exhibits. (d) Exhibit No. Description  104 The cover page from the Company’s Current Report on Form 8-K, dated May 24, 2022, formatted in Inline XBRL. 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. WEST PHARMACEUTICAL SERVICES, INC. /s/ Bernard J. Birkett Bernard J. Birkett Senior Vice President, Chief Financial and Operations Officer May 26, 2022 3 EXHIBIT INDEX Exhibit No. Description 104 The cover page from the Company’s Current Report on Form 8-K, dated May 24, 2022, formatted in Inline XBRL. 4